Get the Stockscreener App
1.84
2.13%
-0.04
After Hours:
1.86
0.02
+1.09%
Elicio Therapeutics Inc stock is traded at $1.84, with a volume of 165.28K.
It is down -2.13% in the last 24 hours and down -38.87% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
See More
Previous Close:
$1.88
Open:
$1.88
24h Volume:
165.28K
Relative Volume:
0.28
Market Cap:
$48.36M
Revenue:
-
Net Income/Loss:
$-40.19M
P/E Ratio:
-0.7848
EPS:
-2.3444
Net Cash Flow:
$-38.49M
1W Performance:
-2.65%
1M Performance:
-38.87%
6M Performance:
-83.21%
1Y Performance:
-83.04%
1-Day Range:
$1.82
$1.90
1-Week Range:
$1.81
$2.02
52-Week Range:
$1.705
$16.00
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
1.84 | 48.36M | 0 | -40.19M | -38.49M | -2.3444 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Ladenburg Thalmann | Buy |
| Mar-10-26 | Initiated | Rodman & Renshaw | Buy |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Why Is ELTX Stock Falling Today? - Stocktwits
Elicio Therapeutics Is Maintained at Buy by B. Riley Securities - Moomoo
Elicio to present new pancreatic cancer trial data at ESMO - Investing.com
Elicio to present new pancreatic cancer trial data at ESMO By Investing.com - Investing.com Nigeria
A pancreatic cancer study missed its main goal. Elicio presents new analyses Oct. 23. - Stock Titan
B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating - marketscreener.com
Elicio Therapeutics, Inc.(NasdaqCM: ELTX) dropped from S&P Global BMI Index - marketscreener.com
Elicio Therapeutics Inc. (NASDAQ: ELTX) Stock Price, News & Analysis - kalkine.com.au
Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines - The Globe and Mail
Elicio Therapeutics (NASDAQ: ELTX) Announces 2026 Annual Meeting Date and Submission Deadlines - Kalkine Media
Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer By Investing.com - Investing.com Nigeria
Elicio Therapeutics (ELTX) sets Sept. 24 cutoff for 2026 proxy proposals - stocktitan.net
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - stocktwits.com
Ladenburg Thalmann assumes Elicio Therapeutics at Buy, target $12 - scanx.trade
Pomerantz investigates Elicio Therapeutics after Phase 2 trial failure - scanx.trade
ELTX Stock Price, Quote & Chart - ChartMill
Elicio Therapeutics closes $15M registered direct offering - scanx.trade
Director at Elicio Therapeutics (ELTX) granted 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (NASDAQ: ELTX) receives 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (ELTX) granted 21,750 options at $2.70 - stocktitan.net
Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities - Moomoo
Elicio Therapeutics (ELTX) director gets 21,750 options at $2.70 - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 10-year stock option grant - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 21,750 stock options - Stock Titan
Director at Elicio Therapeutics (ELTX) gets 21,750 options at $2.70 - stocktitan.net
Elicio Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference - Quiver Quantitative
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com
At Wells Fargo's health conference, Elicio plans one-on-one meetings - Stock Titan
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - GlobeNewswire
Schall Law investigates Elicio after Phase 2 trial failure - scanx.trade
HC Wainwright Has Bearish Forecast for ELTX Q3 Earnings - MarketBeat
Elicio (ELTX) Financial Update: Reported EPS Misses Expectations for This Review; Reaction Snapshot: Shares Move Higher 2.98% in Latest TradingShare Dilution Risk - Vinanet
Elicio Therapeutics' (ELTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Elicio Therapeutics stock price target reiterated at $23 by H.C. Wainwright - Investing.com
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $23 - Moomoo
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Hold Rating - Moomoo
Elicio Therapeutics (ELTX) Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesBanking Earnings Report - Vinanet
ELTX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage InvestmentEstimate Dispersion - Vinanet
Elicio Therapeutics (NASDAQ:ELTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Elicio Therapeutics (ELTX) Stock Forum and Discussion - Moomoo
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Elicio Therapeutics investigation follows Phase 2 failure - scanx.trade
Elicio Therapeutics: Q2 Earnings Snapshot - AOL.com
Elicio Therapeutics added to Russell 2000, 3000 indexes - scanx.trade
Elicio Therapeutics Q2 Results: EPS beats estimate, losses narrow 35% YoY - scanx.trade
Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results - MarketBeat
Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss - Stock Titan
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall - TradingView
Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Elicio Therapeutics, Inc. (ELTX) Free Cash Flow 2025: $37.0M outflow, up 0.5% - Stock Titan
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):